Open AccessPoor Outcomes in Elderly Kidney Transplant Recipients Receiving Alemtuzumab Induction
Author(s) -
Frank P. Hurst,
Maria S. Altieri,
Robert Nee,
Lawrence Y. Agodoa,
Kevin C. Abbott,
Rahul M. Jindal
Publication year - 2011
Publication title -
american journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 85
eISSN - 1421-9670
pISSN - 0250-8095
DOI - 10.1159/000334092
Subject(s) - medicine , alemtuzumab , thymoglobulin , daclizumab , hazard ratio , basiliximab , kidney transplantation , proportional hazards model , cohort , transplantation , surgery , gastroenterology , confidence interval , tacrolimus
Alemtuzumab and rabbit antithymocyte globulin (rATG) are being used with increasing frequency as induction agents in kidney transplantation. Using the US Renal Data Base System, we analyzed the safety profile of these agents in the elderly.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom